The study will enroll a minimum of 65 patients across the United States to evaluate safety and effectiveness of the Recell System.

Avita Medical Limited enrolled the first patient in a study evaluating the Recell System for Soft Tissue Reconstruction at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ.

The prospective multi-center trial of at least 65 patients will compare the clinical performance of conventional skin grafting to the use of the Recell System in combination with more widely meshed autografts on acute full-thickness non-burn skin defects. The study’s two primary effectiveness endpoints are:

• Superior donor skin-sparing, evaluated by comparing the actual expansion ratios of donor skin used to treat the wounds
• Non-inferior incidence of healing by eight weeks post-treatment

Healing will be evaluated by a qualified clinician blinded to the treatment allocation. Additional long-term safety and effectiveness data collected over the course of the 52-week study will include blinded evaluation of scar outcomes and patient treatment preference.“The commencement of this pivotal trial is an important milestone for Avita and a critical step toward making the Recell System broadly available to help patients heal from traumatic or soft tissue wounds with the use of less donor skin than the standard of care,” says Dr. Mike Perry, AVITA Medical Chief Executive Officer, in a news release. “We are pleased to have initiated this registration trial and to have enrolled the first patient in this study.”

“We routinely treat acute non-burn wounds using conventional skin grafting, but that approach results in a donor site wound that adds to the patient’s pain and to the cost of their care,” says Dr. Kevin Foster, Director of the Arizona Burn Center at Valleywise Health Medical Center. “We are eager to evaluate use of the Recell System as a way to reduce the amount of donor skin required. In burn care, where Recell is currently FDA-approved, clinical and health economic benefits have been demonstrated. Relative to burn treatment, autografting for non-burn injuries occurs far more frequently, so this has the potential to be a significant treatment advancement for a large number of patients.”

The pivotal studies leading to the Recell System’s FDA premarket approval for the treatment of acute thermal burns demonstrated that the RECELL System treated burns using 97.5 percent less donor skin when used alone in second-degree burns, and 32 percent less donor skin when used with autograft for third-degree burns. Despite the statistically significant reduction in donor skin required to treat burn patients with the Recell System, burn wounds treated with the Recell System achieved healing comparable to the burn wounds treated with standard of care.